Use of Bidens pilosa L. (Asteraceae) and Curcuma longa L. (Zingiberaceae) to treat intestinal mucositis in mice: Toxico-pharmacological evaluations

C. Bastos,Paulo Henrique Marcelino Ávila,Edvande Xavier dos Santos Filho,Renato I Ávila,A. Batista,S. Fonseca,E. Lima,R. Marreto,E. Mendonça,M. Valadares

DOI: https://doi.org/10.1016/j.toxrep.2015.10.013

2015-10-30

Toxicology Reports

Abstract:

What problem does this paper attempt to address?

Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy

Zichao Yang,Ziqing Liu,Chenglong Xu,Jianwei Xu,Ting Liu,Haiqi He,Ling Li,Yichang Ren,Jianjun Chen

DOI: https://doi.org/10.1016/j.bioorg.2023.106740

IF: 5.307

2023-10-01

Bioorganic Chemistry

Abstract:Programmed death protein 1 (PD-1)/programmed death protein ligand 1 (PD-L1) is one of the most promising immune checkpoints (ICs) in tumor immunology and has been actively pursued as a target for anticancer drug discovery. Based on our previous research in small molecule PD-1/PD-L1 modulators, we designed and synthesized a series of resorcinol biphenyl ether-bearing macrocyclic compounds and evaluated their anti-PD-1/PD-L1 activities. Among them, compound 8d exhibited the highest inhibitory activity against PD-1/PD-L1 interaction with IC50 of 259.7 nM in the homogenous time-resolved fluorescence (HTRF) assay. In addition, 8d displayed in vitro immunomodulatory effects by promoting HepG2 cell death in a HepG2/Jurkat cell co-culture model. Furthermore, 8d effectively inhibited tumor growth (TGI = 74.6% at 40 mg/kg) in a melanoma tumor model in mice without causing obvious toxicity. Moreover, 8d exhibited favorable pharmacokinetics [e.g. high stability, reasonable half-life, and good oral bioavailability (F = 21.5%)]. Finally, molecular modeling studies showed that 8d bound to PD-L1 with high affinity. These results suggest that 8d may serve as a starting point for further development of macrocyclic small molecule-based PD-1/PD-L1 inhibitors for cancer treatment.

biochemistry & molecular biology,chemistry, organic
Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity

Liu Liu,Honghan Zhang,Jie Hou,Yuying Zhang,Luosen Wang,Shijun Wang,Zhiying Yao,Tao Xie,Xiaoan Wen,Qinglong Xu,Liang Dai,Zhiqi Feng,Pu Zhang,Yaojun Wu,Hongbin Sun,Jun Liu,Haoliang Yuan

DOI: https://doi.org/10.1021/acs.jmedchem.4c00102

2024-03-28

Abstract:Programmed death-ligand 1 (PD-L1) has surfaced as a promising therapeutic target for various cancers due to its pivotal role in facilitating tumor immune evasion. Herein, we report a series of novel small-molecule PD-L1 inhibitors exhibiting remarkable inhibitory activity against the PD-1/PD-L1 interaction (X18: IC50 = 1.3 nM) and reinstating the suppressive effect of PD-L1 on T cells (X18: EC50 = 152.8 nM). Crystallographic studies revealed the binding mode of X18 and PD-L1. Through a rational prodrug design approach, we have successfully optimized the oral pharmacokinetic properties of X22, effectively addressing the poor oral pharmacokinetic profile of PD-L1 small-molecule inhibitors. Notably, X22 demonstrated significant antitumor efficacy in murine models of MC38 and CT26 colon cancer through the upregulation of tumor infiltration and cytotoxicity of CD8+ T cells partially. These findings offer promising prospects for the advancement of PD-L1 inhibitors as innovative agents in cancer immunotherapy.
Synthesis and preliminary evaluation of aminophenol derivatives as molecular glues blocking PD-1/PD-L1 interaction

Qiaohong Geng,Yanyan Dong,Peng Jin,Juanjuan Xu,Libin Chen,Xueyuan Du,Mengfei Li,Yuhong Gong,Gaoxing Su,Peifu Jiao,Maosheng Wan

DOI: https://doi.org/10.1016/j.molstruc.2023.135900

IF: 3.841

2023-06-03

Journal of Molecular Structure

Abstract:Discovery of novel small molecules blocking PD-1/PD-L1 interaction is a promising approach mobilizing immune system to fight against cancers. Herein we report the synthesis and identification of a series of aminophenol derivatives as a novel class of PD-1/PD-L1 inhibitors for cancer immunotherapy. Structure based design together with preliminary evaluation of each region of the molecular architecture resulted in identification of ( R )-3-(5-chloro-2-((4-cyanobenzyl)oxy)-4-(((2-methyl-4′-(trifluoromethoxy)-[1,1′-biphenyl]-3-yl)methyl)amino)benzyl)-2-oxooxazolidine-4-carboxylic acid (11e) with an IC 50 value of 21.3 nM. Compound 11e was demonstrated to be a highly potent hPD-L1 inhibitor and showed enhanced inhibitory potency compared to resorcinol derivative (compound 20). Compound 11e was capable of increasing the cytotoxic potency of CD8 + T cells with regard to killing human NSCLC cells.

chemistry, physical
Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction

Chenglong Xu,Zhiqiang Sun,Xuewen Zhang,Qinru Zang,Zichao Yang,Ling Li,Xixiang Yang,Yueyu He,Zeli Ma,Jianjun Chen

DOI: https://doi.org/10.1016/j.bioorg.2024.107376

Abstract:The inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway with small molecules is a promising approach for cancer immunotherapy. Herein, novel small molecules compounds bearing various scaffolds including thiophene, thiazole, tetrahydroquinoline, benzimidazole and indazole were designed, synthesized and evaluated for their inhibitory activity against the PD-1/PD-L1 interaction. Among them, compound Z13 exhibited the most potent activity with IC50 of 189.6 nM in the homogeneous time-resolved fluorescence (HTRF) binding assay. Surface plasmon resonance (SPR) assay demonstrated that Z13 bound to PD-L1 with high affinity (KD values of 231 nM and 311 nM for hPD-L1 and mPD-L1, respectively). In the HepG2/Jurkat T co-culture cell model, Z13 decreased the viability rate of HepG2 cells in a concentration-dependent manner. In addition, Z13 showed significant in vivo antitumor efficacy (TGI = 52.6 % at 40 mg/kg) without obvious toxicity in the B16-F10 melanoma model. Furthermore, flow cytometry analysis demonstrated that Z13 inhibited tumor growth in vivo by activating the tumor immune microenvironment. These findings indicate that Z13 is a promising PD-1/PD-L1 inhibitor deserving further investigation.
Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors

Feng Zhang,Hua Zhang,Shijia Zhou,Jacek Plewka,Ming Wang,Shishi Sun,Caiyun Wu,Qimeng Yu,Mengyu Zhu,Annoor Awadasseid,Yanling Wu,Katarzyna Magiera-Mularz,Wen Zhang

DOI: https://doi.org/10.1016/j.ejmech.2024.116683

IF: 7.088

2024-07-21

European Journal of Medicinal Chemistry

Abstract:A series of novel 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives was designed, synthesized, and evaluated for their antitumor effects as PD-1/PD-L1 inhibitors both in vitro and in vivo . Firstly, the ability of these compounds to block the PD-1/PD-L1 immune checkpoint was assessed using the homogeneous time-resolved fluorescence (HTRF) assay. Two of the compounds can strongly block the PD-1/PD-L1 interaction, with IC 50 values of less than 10 nM, notably, compound HD10 exhibited significant clinical potential by inhibiting the PD-1/PD-L1 interaction with an IC 50 value of 3.1 nM. Further microscale thermophoresis (MST) analysis demonstrated that HD10 had strong interaction with PD-L1 protein. Co-crystal structure (2.7 Å) analysis of HD10 in complex with the PD-L1 protein revealed a strong affinity between the compound and the target PD-L1 dimer. This provides a solid theoretical basis for further in vitro and in vivo studies. Next, a typical cell-based experiment demonstrated that HD10 could remarkably prevent the interaction of hPD-1 293 T cells from human recombinant PD-L1 protein, effectively restoring T cell function, and promoting IFN-γ secretion in a dose-dependent manner. Moreover, HD10 was effective in suppressing tumor growth (TGI = 57.31 %) in a PD-1/PD-L1 humanized mouse model without obvious toxicity. Flow cytometry, qPCR, and immunohistochemistry data suggested that HD10 inhibits tumor growth by activating the immune system in vivo . Based on these results, it seems likely that HD10 is a promising clinical candidate that should be further investigated.

chemistry, medicinal
Discovery of [1,2,4]Triazolo[4,3-A]pyridines As Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Mingze Qin,Qi Cao,Shuaishuai Zheng,Ye Tian,Haotian Zhang,Jun Xie,Hongbo Xie,Yajing Liu,Yanfang Zhao,Ping Gong

DOI: https://doi.org/10.1021/acs.jmedchem.9b00312

IF: 8.039

2019-01-01

Journal of Medicinal Chemistry

Abstract:Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-molecule inhibitors is an emerging immunotherapeutic approach. A novel series of [1,2,4]triazolo[4,3- a]pyridines were designed and found to be potent inhibitors of the PD-1/PD-L1 interaction. Among them, compound A22 exhibited the most potent activity, as assessed by homogenous time-resolved fluorescence assay, with an IC50 of 92.3 nM. Furthermore, A22 dose-dependent elevated interferon-γ production in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. We concluded that A22 is a promising lead compound for the development of inhibitors of the PD-1/PD-L1 interaction. In addition, we explored the structure-activity relationships of the newly synthesized [1,2,4]triazolo[4,3- a]pyridines and demonstrated that a ring fusion strategy can be employed for designing analogues of the Bristol-Myers Squibb chemical series. These studies pave the way for future drug design.
Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Tianyu Wang,Shi Cai,Mingming Wang,Wanheng Zhang,Kuojun Zhang,Dong Chen,Zheng Li,Sheng Jiang

DOI: https://doi.org/10.1021/acs.jmedchem.1c00010

IF: 8.039

2021-05-31

Journal of Medicinal Chemistry

Abstract:With the successful clinical application of anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) monoclonal antibodies (mAb), targeting the PD-1/PD-L1 interaction has become a promising method for the discovery of cancer therapy. Due to the inherent limitations of antibodies, it is necessary to search for small-molecule inhibitors against the PD-1/PD-L1 axis. We report the design, synthesis, and evaluation in vitro and in vivo of a series of novel biphenyl pyridines as the inhibitors of PD-1/PD-L1. 2-(((2-Methoxy-6-(2-methyl-[1,1′-biphenyl]-3-yl)pyridin-3-yl)methyl)amino)ethan-1-ol (24) was found to inhibit the PD-1/PD-L1 interaction with an IC50 value of 3.8 ± 0.3 nM and enhance the killing activity of tumor cells by immune cells. Compound 24 displays great pharmacokinetics (oral bioavailability of 22%) and significant in vivo antitumor activity in a CT26 mouse model. Flow cytometry and immunohistochemistry data indicated that compound 24 activates the immune activity in tumors. These results suggest that compound 24 is a promising small-molecule inhibitor against the PD-1/PD-L1 axis and merits further development.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00010?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00010</a>.Data of PD-1/PD-L1 TR-FRET assay, in vivo antitumor activity study of compound 24, compound 1 and PD-L1 antibody, binding affinity of compound 1 and 24 to PD-L1 by microscale thermophoresis assay, and 1H NMR, 13C NMR, and HPLC spectra of the final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00010/suppl_file/jm1c00010_si_001.pdf">PDF</a>)Docking of compound 24 with PD-L1 from 5J89 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00010/suppl_file/jm1c00010_si_002.csv">CSV</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00010/suppl_file/jm1c00010_si_003.pdb">PDB</a>)This article has not yet been cited by other publications.

chemistry, medicinal
Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy

Hongbo Zhang,Yu Xia,Chunqiu Yu,Huijie Du,Jinchang Liu,Hui Li,Shihui Huang,Qihua Zhu,Yungen Xu,Yi Zou

DOI: https://doi.org/10.3390/molecules26113347

IF: 4.6

2021-06-02

Molecules

Abstract:Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction is currently the focus in the field of cancer immunotherapy, and so far, several monoclonal antibodies (mAbs) have achieved encouraging outcomes in cancer treatment. Despite this achievement, mAbs-based therapies are struggling with limitations including poor tissue and tumor penetration, long half-life time, poor oral bioavailability, and expensive production costs, which prompted a shift towards the development of the small-molecule inhibitors of PD-1/PD-L1 pathways. Even though many small-molecule inhibitors targeting PD-1/PD-L1 interaction have been reported, their development lags behind the corresponding mAb, partly due to the challenges of developing drug-like small molecules. Herein, we report the discovery of a series of novel inhibitors targeting PD-1/PD-L1 interaction via structural simplification strategy by using BMS-1058 as a starting point. Among them, compound A9 stands out as the most promising candidate with excellent PD-L1 inhibitory activity (IC50 = 0.93 nM, LE = 0.43) and high binding affinity to hPD-L1 (KD = 3.64 nM, LE = 0.40). Furthermore, A9 can significantly promote the production of IFN-γ in a dose-dependent manner by rescuing PD-L1 mediated T-cell inhibition in Hep3B/OS-8/hPD-L1 and CD3-positive T cells co-culture assay. Taken together, these results suggest that A9 is a promising inhibitor of PD-1/PD-L1 interaction and is worthy for further study.

chemistry, multidisciplinary,biochemistry & molecular biology
Design, Synthesis, And Evaluation Of O-(Biphenyl-3-Ylmethoxy)Nitrophenyl Derivatives As Pd-1/Pd-L1 Inhibitors With Potent Anticancer Efficacy In Vivo

Yiqiang OuYang,Jian Gao,Lei Zhao,Junfeng Lu,Haiqing Zhong,Hua Tang,Shuanglong Jin,Lu Yue,Yuezhen Li,Wenjie Guo,Qiang Xu,Yisheng Lai

DOI: https://doi.org/10.1021/acs.jmedchem.1c00370

IF: 8.039

2021-01-01

Journal of Medicinal Chemistry

Abstract:Two series of novel o-(biphenyl-3-ylmethoxy)nitrophenyl compounds (A1-31 and B1-17) were designed as programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors. All compounds showed significant inhibitory activity with IC50 values ranging from 2.7 to 87.4 nM except compound A17, and compound B2 displayed the best activity. Further experiments showed that B2 bound to the PD-L1 protein without obvious toxicity in Lewis lung carcinoma (LLC) cells. Furthermore, B2 significantly promoted interferon-gamma secretion in a dose-dependent manner in vitro and in vivo. Especially, B2 exhibited potent in vivo anticancer efficacy in an LLC-bearing allograft mouse model at a low dose of 5 mg/kg, which was more active than BMS-1018 (tumor growth inhibition rate: 48.5% vs 17.8%). A panel of immunohistochemistry and flow cytometry assays demonstrated that B2 effectively counteracted PD-1-induced immunosuppression in the tumor microenvironment, thereby triggering antitumor immunity. These results indicate that B2 is a promising PD-1/PD-L1 inhibitor worthy of further development.
Investigation of PD-1H in DEN-induced Mouse Liver Cancer Model.

C-J Lei,B. Wang,Z-X Long,H. Ren,Q-Y Pan,Y. Li

DOI: https://doi.org/10.26355/eurrev_201808_15716

2018-01-01

European review for medical and pharmacological sciences

Abstract:OBJECTIVE:Immune therapy has recently become a novel strategy for treating liver cancer, making it of critical importance to identify novel targets for treatment. Programmed death-1 homology (PD-1H) is one newly discovered negative co-stimulating molecule, and plays important regulatory roles in suppressing T cell activation. However, the expression or function of PD-1H in liver tumors has not been reported.MATERIALS AND METHODS:Liver cancer tissues were collected from The Cancer Genome Atlas (TCGA) (http://tcga-data.nci-nih.gov). This study then utilized diethylnitrosamine (DEN) induced liver cancer mice, on which PD-1H monoclonal antibody and PD-1H extra-cellular Fc domain fusion protein were injected intraperitoneal. General status, gross morphology of liver tissues was examined, followed by hematoxylin-eosin (HE) staining and plotting survival curve.RESULTS:Among TCGA samples, PD-1H expression was significantly elevated. Induced liver cancer mice showed depressed mental status, early onset of hepatitis and liver cirrhosis. Five mice dead in model group (mortality=33.33%). No natural death occurred in control group. Injection of PD-1H-Fc-Ig fusion and PD-1H monoclonal antibody improved the condition to certain extents, with morality at about 20%. Comparing to DEN group, combined treatment group showed significantly fewer tumor lesion on liver surface, with increased body weight and lower liver-body weight ratio. HE staining showed significantly elevated ratio of normal cells in combined treatment group, although large amounts of cancer cells still existed.CONCLUSIONS:Blocking of PD-1H signal pathway could suppress liver cancer cell growth, decrease mouse mortality, indicating promising application of PD-1H in tumor immune therapy.
Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Lexian Tong,Pinrao Song,Kailong Jiang,Lei Xu,Tingting Jin,Peipei Wang,Xiaobei Hu,Sui Fang,Anhui Gao,Yubo Zhou,Tao Liu,Jia Li,Yongzhou Hu

DOI: https://doi.org/10.1016/j.ejmech.2019.03.062

IF: 7.088

2019-01-01

European Journal of Medicinal Chemistry

Abstract:Through virtual screening, we identified the lead compound MCL1020, which exhibited modest CHK1 inhibitory activity. Then a series of 5-(pyrimidin-2-ylamino)picolinonitrile derivatives as CHK1 inhibitors were discovered by further rational optimization. One promising molecule. (R)-17, whose potency was one of the best, had an IC50 of 0.4 nM with remarkable selectivity (>4300-fold CHK1 vs. CHK2). Compound (R)-17 effectively inhibited the growth of malignant hematopathy cell lines especially Z-138 (IC50: 0.013 mu M) and displayed low affinity for hERG (IC50> 40 mu M). Moreover, (R)-17 significantly suppressed the tumor growth in Z-138 cell inoculated xenograft model (20 mg/kg I.V., TGI = 90.29%) as a single agent with body weight unaffected. Taken together, our data demonstrated compound (R)-17 could be a promising drug candidate for the treatment of hematologic malignancies. (C) 2019 Published by Elsevier Masson SAS.
Discovery of Phenyl-Linked Symmetric Small Molecules As Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Yizhe Wu,Yu Zhang,Yu Guo,Zhichao Pan,Shichun Zhong,Xinxin Jin,Weihao Zhuang,Sikang Chen,Jian Gao,Wenhai Huang,Xiaowu Dong,Jinxin Che

DOI: https://doi.org/10.1016/j.ejmech.2021.113637

IF: 7.088

2021-01-01

European Journal of Medicinal Chemistry

Abstract:Programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) is one of the most promising targets in the field of immune checkpoint blockade therapy. Beginning with our exploration of linkers and structure-activity relationship research, we found that the aromatic ring could replace the linker and aryl group to maintain the satisfactory activity of classic triaryl scaffold inhibitor. Based on previous studies, we designed and synthesized a series of C-2-symmetric phenyl-linked compounds, and further tail optimization afforded the inhibitors, which displayed promising inhibitory activity against the PD-1/PD-L1 interaction with IC50 value at the single nanomolar range (C13-C15). Further cell-based PD-1/PD-L1 blockade bioassays indicated that these C-2-symmetric molecules could significantly inhibit the PD-1/PD-L1 interaction at the cellular level and restore T cells' immune function at the safety concentrations. The discovery of these phenyl-linked symmetric small molecules showed the potential of simplified-linker and C-2-symmetric strategy and provided a basis for developing symmetric small molecule inhibitors of PD-1/PD-L1 interaction. Moreover, C13 and C15 performed stable binding modes to PD-L1 dimeric after computational docking and dynamic simulation, which may serve as a good starting point for further development. (C) 2021 Elsevier Masson SAS. All rights reserved.
Discovery and Crystallography Study of Novel Biphenyl Ether and Oxadiazole Thioether (Non-Arylmethylamine)-Based Small-Molecule PD-1/PD-L1 Inhibitors as Immunotherapeutic Agents

Jin Liu,Yao Cheng,Lin Yuan,Ting Liu,Yong Ruan,Yichang Ren,Ling Li,Sheng Jiang,Yibei Xiao,Jianjun Chen

DOI: https://doi.org/10.1021/acs.jmedchem.3c01141

2023-09-28

Abstract:Current small-molecule PD-1/PD-L1 inhibitors are mainly based on the arylmethylamine/biphenyl core scaffold. Herein, we designed for the first time a series of non-arylmethylamine analogues (oxadiazole thioether derivatives) as small-molecule PD-1/PD-L1 inhibitors. Among them, compound LP23 exhibited the most potent PD-L1 inhibitory activity with an IC50 of 16.7 nM, 3.2-fold better than the lead BMS-202 (IC50 = 53.6 nM). The X-ray crystal structure of LP23 in complex with PD-L1 was solved at a resolution of 2.6 Å, which further confirmed the high binding affinity of LP23 to PD-L1. In the HepG2/Jurkat T cell co-culture model, LP23 effectively promoted HepG2 cell death by restoring the immune function of T cells. In addition, LP23 showed excellent in vivo antitumor efficacy (TGI = 88.6% at 30 mg/kg) and benign toxicity profiles in a B16-F10 tumor model by modulating PD-L1. In summary, LP23 represents the first non-arylmethylamine-based small-molecule PD-1/PD-L1 inhibitor worthy of further investigation.
Design, Synthesis, and Biological Evaluation of Chroman Derivatives as PD-1/PD-L1 Antagonists

Luosen Wang,Jie Hou,Peng Cao,Zhiying Yao,Shijun Wang,Yuying Zhang,Sheng Wang,Haoliang Yuan,Liu Liu

DOI: https://doi.org/10.1021/acs.jcim.4c00455

2024-06-24

Abstract:Programmed death-ligand 1 (PD-L1) has emerged as a promising therapeutic target for various cancers due to its crucial role in promoting tumor immune evasion. Here, we report a novel class of chroman-like small-molecule PD-L1 inhibitors exhibiting significant activity in inhibiting the PD-1/PD-L1 interaction. Employing a "ring-close" strategy for conformational restriction, we have achieved compound C27, which demonstrates superior PD-1/PD-L1 inhibitory activity compared to the positive control. Molecular dynamics simulation and binding free energy calculation predict that (R)-C27 with inhibitory activity surpassed (S)-C27. The experimental results from bioassay and X-ray structural analysis corroborate these findings. All these results collectively indicate that (R)-C27 is a promising lead compound deserving further exploration.
Electrical stimulation of the limbic system of brain (visceral brain) in the waking animals.

Anand Bk,S. Dua

The Indian Journal of Medical Research

Abstract:
Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo

Yiqiang OuYang,Jian Gao,Lei Zhao,Junfeng Lu,Haiqing Zhong,Hua Tang,Shuanglong Jin,Lu Yue,Yuezhen Li,Wenjie Guo,Qiang Xu,Yisheng Lai

DOI: https://doi.org/10.1021/acs.jmedchem.1c00370

IF: 8.039

2021-01-01

Journal of Medicinal Chemistry

Abstract:Two series of novel o-(biphenyl-3-ylmethoxy)nitrophenyl compounds (A1-31 and B1-17) were designed as programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors. All compounds showed significant inhibitory activity with IC50 values ranging from 2.7 to 87.4 nM except compound A17, and compound B2 displayed the best activity. Further experiments showed that B2 bound to the PD-L1 protein without obvious toxicity in Lewis lung carcinoma (LLC) cells. Furthermore, B2 significantly promoted interferon-gamma secretion in a dose-dependent manner in vitro and in vivo. Especially, B2 exhibited potent in vivo anticancer efficacy in an LLC-bearing allograft mouse model at a low dose of 5 mg/kg, which was more active than BMS-1018 (tumor growth inhibition rate: 48.5% vs 17.8%). A panel of immunohistochemistry and flow cytometry assays demonstrated that B2 effectively counteracted PD-1-induced immunosuppression in the tumor microenvironment, thereby triggering antitumor immunity. These results indicate that B2 is a promising PD-1/PD-L1 inhibitor worthy of further development.
Design, Synthesis and Biological Evaluation of Biphenyl-1,2,3-Triazole Hybrid Analogues as PD-1/PD-L1 Inhibitors

Shijia Zhou,Suresh Narva,Mengda Wu,Ming Wang,Feng Zhang,Chenfeng Shen,Annoor Awadasseid,Wen Zhang

DOI: https://doi.org/10.3923/ijp.2024.106.114

2024-01-15

International Journal of Pharmacology

Abstract:Background and Objective: Inhibition of PD-1/PD-L1 with small molecules has shown promise as a potential therapy for certain cancers. This study aimed to synthesize and evaluate the antineoplastic activity of thirty biphenyl-1,2,3-triazole hybrid analogues. Materials and Methods: The effectiveness of inhibitors against PD-1/PD-L1 binding was evaluated using Homogeneous Time-Resolved Fluorescence (HTRF), the CCK-8 assay to assess the ability of the compounds to inhibit tumor cell proliferation and the wound-healing assay to study cell migration and cell-cell interaction. Results: Current findings indicated that compounds 6d, 6e and 6h exhibit strong anti-proliferative activity against A549, MDA-MB-231 and HCC827 cancer cells via the non-immune pathway. Specifically, they displayed potent inhibitory effects against A549 cells, with IC50 values of 0.315±0.13, 0.821±0.07 and 0.576±0.15 μM, respectively, suggesting that they have potential as anti-lung cancer drugs. Despite their potent anti-tumor activity, our compounds showed only weak inhibition of the PD-1/PD-L1 interaction, as evaluated by HTRF analysis. Conclusion: Results of the present study indicated that compounds 6d, 6e and 6h have anticancer efficacy through both immunological and non-immune mechanisms, specifically by inhibiting the PD-1/PD-L1 combination.

pharmacology & pharmacy
Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy

Yongling Xu,Huijie Du,Weibo Guo,Beibei Liu,Wenxin Yan,Chi Zhang,Long Qin,Jingling Huang,Hongxia Wang,Shiqi Wu,Weijie Ren,Yi Zou,Jie Wang,Qihua Zhu,Yungen Xu,Hongfeng Gu

DOI: https://doi.org/10.1021/acs.jmedchem.3c02362

IF: 8.039

2024-02-14

Journal of Medicinal Chemistry

Abstract:Inhibition of the PD-1/PD-L1 interaction through small-molecule inhibitors is a promising therapeutic approach in cancer immunotherapy. Herein, we utilized BMS-202 as the lead compound to develop a series of novel PD-1/PD-L1 small-molecule inhibitors with a naphthyridin scaffold. Among these compounds, X14 displayed the most potent inhibitory activity for the PD-1/PD-L1 interaction (IC(50) = 15.73 nM). Furthermore, X14 exhibited good binding affinity to both human PD-L1 (K(D) = 14.62 nM) and...

chemistry, medicinal
Discovery of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction Inhibitors Bearing an Indoline Scaffold.

Mingze Qin,Qi Cao,Xia Wu,Chunyang Liu,Shuaishuai Zheng,Hongbo Xie,Ye Tian,Jun Xie,Yanfang Zhao,Yunlei Hou,Xian Zhang,Boxuan Xu,Haotian Zhang,Xiaobo Wang

DOI: https://doi.org/10.1016/j.ejmech.2019.111856

IF: 7.088

2020-01-01

European Journal of Medicinal Chemistry

Abstract:Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy. Here, a novel series of indoline-containing compounds were developed, among which, A13 was identified as the most promising PD-1/PD-L1 pathway inhibitor. At the biochemical level, A13 demonstrated strong inhibition of the PD-1/PD-L1 interaction, with an IC50 of 132.8 nM. Notably, it exhibited outstanding immunoregulatory activity, and significantly elevated interferon-gamma secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. Therefore, A13 could be employed as a suitable lead compound for further design of non-peptide inhibitors targeting the PD-1/PD-L1 interaction. In addition, the preliminary structure-activity relationships of these new indoline compounds were investigated in this study, providing valuable information for future drug development. (C) 2019 Elsevier Masson SAS. All rights reserved.
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation

Tianyu Wang,Shi Cai,Yao Cheng,Wanheng Zhang,Minmin Wang,Huiyong Sun,Binghua Guo,Zheng Li,Yibei Xiao,Sheng Jiang

DOI: https://doi.org/10.1021/acs.jmedchem.1c01682

IF: 8.039

2022-02-21

Journal of Medicinal Chemistry

Abstract:Several monoclonal antibodies targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway have been used successfully in anticancer immunotherapy. Inherent limitations of antibody-based therapies remain, however, and alternative small-molecule inhibitors that can block the PD-1/PD-L1 axis are urgent needed. Herein, we report the discovery of compound 17 as a bifunctional inhibitor of PD-1/PD-L1 interactions. 17 inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1. 17 promotes cell-surface PD-L1 internalized into the cytosol and induces the degradation of PD-L1 in tumor cells through a lysosome-dependent pathway. Furthermore, 17 suppresses tumor growth in vivo by activating antitumor immunity. These results demonstrate that 17 targets the PD-1/PD-L1 axis and induces PD-L1 degradation.

chemistry, medicinal

Use of Bidens pilosa L. (Asteraceae) and Curcuma longa L. (Zingiberaceae) to treat intestinal mucositis in mice: Toxico-pharmacological evaluations

Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy

Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity

Synthesis and preliminary evaluation of aminophenol derivatives as molecular glues blocking PD-1/PD-L1 interaction

Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction

Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors

Discovery of [1,2,4]Triazolo[4,3-A]pyridines As Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy

Design, Synthesis, And Evaluation Of O-(Biphenyl-3-Ylmethoxy)Nitrophenyl Derivatives As Pd-1/Pd-L1 Inhibitors With Potent Anticancer Efficacy In Vivo

Investigation of PD-1H in DEN-induced Mouse Liver Cancer Model.

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Discovery of Phenyl-Linked Symmetric Small Molecules As Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Discovery and Crystallography Study of Novel Biphenyl Ether and Oxadiazole Thioether (Non-Arylmethylamine)-Based Small-Molecule PD-1/PD-L1 Inhibitors as Immunotherapeutic Agents

Design, Synthesis, and Biological Evaluation of Chroman Derivatives as PD-1/PD-L1 Antagonists

Electrical stimulation of the limbic system of brain (visceral brain) in the waking animals.

Design, Synthesis, and Evaluation of <i>o</i>-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy <i>In Vivo</i>

Design, Synthesis and Biological Evaluation of Biphenyl-1,2,3-Triazole Hybrid Analogues as PD-1/PD-L1 Inhibitors

Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy

Discovery of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction Inhibitors Bearing an Indoline Scaffold.

Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation